Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 31,874,568
  • Shares Outstanding, K 223,180
  • Annual Sales, $ 3,084 M
  • Annual Income, $ 399,000 K
  • 36-Month Beta 1.40
  • Price/Sales 10.34
  • Price/Cash Flow 23.80
  • Price/Book 3.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
135.50 +5.40%
on 08/23/17
149.34 -4.37%
on 09/05/17
+4.62 (+3.34%)
since 08/22/17
3-Month
117.17 +21.89%
on 07/06/17
149.34 -4.37%
on 09/05/17
+16.59 (+13.14%)
since 06/22/17
52-Week
96.18 +48.49%
on 05/26/17
149.34 -4.37%
on 09/05/17
+9.13 (+6.83%)
since 09/22/16

Most Recent Stories

More News
The Medicines Co. Continues to Focus on Pipeline Development

The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.

MDCO : 35.44 (+1.40%)
MNK : 34.83 (-0.09%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)
Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions

Bayer (BAYRY) remains focused on developing its pipeline and acquisitions in order to boost its portfolio.

BAYRY : 33.0300 (-0.09%)
REGN : 432.72 (-0.17%)
MON : 119.77 (+0.31%)
ALXN : 142.82 (-0.07%)
Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher

Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.

RDY : 37.66 (-0.16%)
ALXN : 142.82 (-0.07%)
Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day

Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day

AKTX : 8.18 (-6.41%)
WERN : 35.55 (-0.56%)
COT : 14.94 (-0.13%)
ALXN : 142.82 (-0.07%)
Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why

On Thursday, shares of biopharmaceutical company Akari Therapeutics (AKTX) are skyrocketing, up over 60% in midday trading--the stock was up 90% in premarket trading--after it announced it would advance...

AKTX : 8.18 (-6.41%)
ALXN : 142.82 (-0.07%)
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up

Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.

ALNY : 113.80 (+0.78%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
ALXN : 142.82 (-0.07%)
Karyopharm's Liposarcoma Candidate Superior in Phase II Study

Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.

ESALY : 52.5300 (+1.19%)
JNJ : 131.39 (-0.27%)
KPTI : 10.63 (+1.43%)
ALXN : 142.82 (-0.07%)
Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session

Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.

ALNY : 113.80 (+0.78%)
ALXN : 142.82 (-0.07%)
Novartis Poised to Grow on Oncology Portfolio & Biosimilars

Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.

NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
AMGN : 185.76 (-0.47%)
ALXN : 142.82 (-0.07%)
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status

ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.

PDLI : 3.17 (-3.06%)
PRQR : 6.20 (+7.83%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 144.25
1st Resistance Point 143.53
Last Price 142.82
1st Support Level 141.78
2nd Support Level 140.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.